The new patent entitled, ‘Oligonucleotides for Treatment of Prostate and other Cancers,’ includes coverage for antisense and siRNA compositions that reduce the amount of active Heat Shock Protein 27 (Hsp27) in Hsp27 expressing cells.
OGX-427, a second-generation antisense drug that is designed to reduce production of Hsp27, a cell-survival protein, is encompassed by the granted claims.
OncoGenex said the current patent patent is licensed from from The University of British Columbia.
OncoGenex president and CEO Scott Cormack said the patent comes as they continue to evaluate additional Phase II clinical trials and development plans for OGX-427.